MA30323B1 - Compositions comprenant des cellules souches embryonnaires humaines et leurs derives, procedes d'utilisation et procedes de preparation - Google Patents

Compositions comprenant des cellules souches embryonnaires humaines et leurs derives, procedes d'utilisation et procedes de preparation

Info

Publication number
MA30323B1
MA30323B1 MA31267A MA31267A MA30323B1 MA 30323 B1 MA30323 B1 MA 30323B1 MA 31267 A MA31267 A MA 31267A MA 31267 A MA31267 A MA 31267A MA 30323 B1 MA30323 B1 MA 30323B1
Authority
MA
Morocco
Prior art keywords
methods
factor
derivatives
human embryonic
embryonic stem
Prior art date
Application number
MA31267A
Other languages
English (en)
Inventor
Geeta Shroff
Original Assignee
Geeta Shroff
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Geeta Shroff filed Critical Geeta Shroff
Publication of MA30323B1 publication Critical patent/MA30323B1/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
    • A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/31—Pituitary sex hormones, e.g. follicle-stimulating hormone [FSH], luteinising hormone [LH]; Chorionic gonadotropins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/38—Hormones with nuclear receptors
    • C12N2501/39—Steroid hormones
    • C12N2501/392—Sexual steroids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Reproductive Health (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Neurology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Neurosurgery (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)

Abstract

La présente invention concerne une composition pharmaceutique qui comprend des préparations de cellules souches embryonnaires humaines (human Embryonic Stem; hES) et leurs dérivés, ainsi que des procédés permettant de les transplanter dans un organisme humain dans lequel la transplantation se traduit par l'inversion clinique des symptômes, la guérison, la stabilisation ou l'arrêt de la dégénérescence d'une grande diversité d'états médicaux, de maladies et d'affections actuellement incurables et mortels. L'invention concerne également des procédés innovants de préparation de lignées de cellules souches innovantes exemptes de produits animaux, de cellules nourricières, de facteurs de croissance, de facteur inhibiteur de la leucémie, de combinaisons de minéraux complémentaires, de suppléments d'acides aminés, de suppléments vitaminés, de facteur de croissance des fibroblastes, de facteur Steel associé à la membrane, de facteur Steel soluble et de milieu conditionné. La présente invention concerne en outre l'isolement, la culture, l'entretien, l'expansion, la différenciation, le stockage et la conservation de telles cellules souches.
MA31267A 2006-03-07 2008-10-03 Compositions comprenant des cellules souches embryonnaires humaines et leurs derives, procedes d'utilisation et procedes de preparation MA30323B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN582DE2006 2006-03-07
IN1500DE2006 2006-06-26
US84435006P 2006-09-14 2006-09-14

Publications (1)

Publication Number Publication Date
MA30323B1 true MA30323B1 (fr) 2009-04-01

Family

ID=54150153

Family Applications (1)

Application Number Title Priority Date Filing Date
MA31267A MA30323B1 (fr) 2006-03-07 2008-10-03 Compositions comprenant des cellules souches embryonnaires humaines et leurs derives, procedes d'utilisation et procedes de preparation

Country Status (23)

Country Link
US (9) US10545135B2 (fr)
EP (11) EP2422797A3 (fr)
JP (2) JP5649786B2 (fr)
KR (2) KR101505202B1 (fr)
CN (2) CN101420964A (fr)
AP (1) AP2949A (fr)
AU (1) AU2007257594B2 (fr)
BR (1) BRPI0708576A2 (fr)
CA (1) CA2644922C (fr)
CR (1) CR10345A (fr)
CU (1) CU20080161A7 (fr)
DK (1) DK1993575T3 (fr)
EA (1) EA027648B9 (fr)
EC (1) ECSP088799A (fr)
GE (1) GEP20135796B (fr)
IL (1) IL193702A (fr)
MA (1) MA30323B1 (fr)
MX (1) MX347303B (fr)
MY (1) MY154677A (fr)
NO (1) NO20084181L (fr)
NZ (2) NZ594639A (fr)
PH (1) PH12014501028A1 (fr)
WO (1) WO2007141657A2 (fr)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP2949A (en) 2006-03-07 2014-07-31 Shroff Geeta Compositions comprising human embryonic stem cellsand their derivatives, methods of use, and method s of preparation
ATE530638T1 (de) 2007-04-26 2011-11-15 Univ Ramot Pluripotente autologe stammzellen aus der mündlichen oder gastrointestinalen schleimhaut
US20100266552A1 (en) * 2007-05-28 2010-10-21 Monash University Treatment of chronic lung disease
US20090291061A1 (en) * 2008-05-21 2009-11-26 Riordan Neil H Stem cell therapy for blood vessel degeneration
EP2296672B1 (fr) * 2008-06-11 2015-09-16 Fresenius Medical Care Deutschland GmbH Milieu conditionné pour cellules progéniteurs du foie
WO2010006261A1 (fr) * 2008-07-10 2010-01-14 Hong John J Procédés d’induction de la migration et de la spécialisation des cellules souches à l’aide d’ec-18
EP4176888A1 (fr) * 2008-11-14 2023-05-10 ViaCyte, Inc. Encapsulation de cellules pancréatiques dérivées de cellules souches pluripotentes humaines
GB201111244D0 (en) * 2011-06-30 2011-08-17 Konink Nl Akademie Van Wetenschappen Knaw Culture media for stem cells
US8377432B2 (en) * 2009-09-02 2013-02-19 Khay-Yong Saw Method and composition for neochondrogenesis
EP2473598B1 (fr) 2009-09-04 2017-03-22 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Procédé d'amélioration de la stabilité du génome et de l'élongation du télomère dans des cellules souches embryonnaires
WO2011047345A2 (fr) * 2009-10-15 2011-04-21 Tai June Yoo Méthodes de traitement de maladies ou d'affections faisant appel à des cellules souches mésenchymateuses
WO2011070974A1 (fr) * 2009-12-07 2011-06-16 国立大学法人名古屋大学 Préparation de cellules pour traiter le cancer de la prostate comprenant des cellules souches mésenchymateuses dérivées de tissu adipeux
CA2795401A1 (fr) * 2010-04-08 2011-10-13 Anthrogenesis Corporation Traitement de la sarcoidose au moyen de cellules souches du sang placentaire
WO2011145110A1 (fr) 2010-05-15 2011-11-24 Subhadra Dravida Nouvelle composition nutritive du plasma sanguin du cordon ombilical et procédé de préparation de celle-ci
EP2637711B1 (fr) * 2010-11-10 2024-03-27 ProKidney Formulations injectables pour la régénération d'organe
FR2986537B1 (fr) * 2012-02-07 2014-03-28 Oreal Procede d'evaluation d'actif(s) apte(s) a preserver la fonctionnalite des cellules souches epitheliales
EP2838995A4 (fr) * 2012-04-16 2016-01-06 Univ California Thérapie oculaire utilisant des microvésicules de cellules souches embryonnaires
WO2014089121A2 (fr) * 2012-12-03 2014-06-12 Thomas Ichim Administration rétrograde de cellules et d'acides nucléiques pour le traitement de maladies cardiovasculaires
US9265458B2 (en) 2012-12-04 2016-02-23 Sync-Think, Inc. Application of smooth pursuit cognitive testing paradigms to clinical drug development
WO2014116786A1 (fr) * 2013-01-25 2014-07-31 Zietchick Research Institute,Llc Utilisation de la gonadotrophine chorionique humaine dans le traitement de l'infirmité motrice cérébrale et/ou de ses comorbidités
CN103961373A (zh) 2013-02-04 2014-08-06 西比曼生物科技（上海）有限公司 异体间质血管层细胞和异体间充质祖细胞在预防或治疗骨性关节炎中的应用
US9380976B2 (en) 2013-03-11 2016-07-05 Sync-Think, Inc. Optical neuroinformatics
ITMI20130513A1 (it) * 2013-04-05 2014-10-06 Euroclone S P A Metodo diagnostico per patologie autoimmuni del fegato
US10597633B2 (en) 2014-05-16 2020-03-24 Koninklijke Nederlandse Akademie Van Wetenschappen Culture method for organoids
KR101686315B1 (ko) 2015-01-09 2016-12-13 이화여자대학교 산학협력단 편도 유래 중간엽 줄기세포로부터 슈반 세포의 분화 방법
KR102036029B1 (ko) 2015-03-11 2019-10-24 이화여자대학교 산학협력단 골수 부전 예방 또는 치료용 조성물
KR20160109356A (ko) 2015-03-11 2016-09-21 이화여자대학교 산학협력단 자가 면역 질환 예방 또는 치료용 조성물
KR20160109358A (ko) 2015-03-11 2016-09-21 이화여자대학교 산학협력단 면역 질환 예방 또는 치료용 조성물
KR101885122B1 (ko) 2015-03-26 2018-09-11 이화여자대학교 산학협력단 분화촉진 및 지속형 스페로이드 형태의 편도 유래 줄기세포의 배양 방법
WO2016196661A1 (fr) 2015-06-01 2016-12-08 Memorial Sloan-Kettering Cancer Center Procédés de différenciation in vitro de neurones dopaminergiques mésencéphaliques (mda)
CA3013623A1 (fr) 2016-02-05 2017-08-10 Memorial Sloan-Ketering Cancer Center Procedes de differenciation de precurseurs de lignees ectodermiques derives de cellules souches
CN105749254A (zh) * 2016-02-28 2016-07-13 深圳爱生再生医学科技有限公司 用于治疗血管性痴呆的干细胞制剂及其制备方法和应用
GB201603569D0 (en) 2016-03-01 2016-04-13 Koninklijke Nederlandse Akademie Van Wetenschappen Improved differentiation method
EP3464567A4 (fr) 2016-05-27 2020-01-08 Memorial Sloan Kettering Cancer Center Procédés de différenciation de propriocepteurs dérivés des cellules souches
US20180242590A1 (en) * 2016-09-23 2018-08-30 Peter Friedman Compositions and methods for treating citrus plants infected with bacteria and for promoting general agricultural health
CN106177918A (zh) * 2016-09-30 2016-12-07 广州赛莱拉干细胞科技股份有限公司 一种间充质干细胞注射液及其制备方法和应用
CA3052124C (fr) * 2017-01-31 2024-06-25 Osaka University Procede de controle de differenciation pour cellules souches pluripotentes
US11590175B2 (en) 2017-08-23 2023-02-28 Merakris Therapeutics Llc Compositions containing amniotic components and methods for preparation and use thereof
KR102130493B1 (ko) 2018-07-11 2020-07-06 이화여자대학교 산학협력단 건선 예방 또는 치료용 조성물
KR102089476B1 (ko) 2018-07-11 2020-03-16 이화여자대학교 산학협력단 피부 염증 질환 예방 또는 치료용 조성물
KR20190120141A (ko) 2019-10-16 2019-10-23 이화여자대학교 산학협력단 골수 부전 예방 또는 치료용 조성물
KR20210119766A (ko) * 2020-03-25 2021-10-06 서울대학교병원 인간 배아줄기세포 유래 중간엽 줄기세포를 포함하는 망막색소변성의 예방 또는 치료용 약학적 조성물
CA3183958A1 (fr) 2020-06-26 2021-12-30 Minerva Biotechnologies Corporation Procedes de derivation de neurones dopaminergiques a partir de cellules souches pluripotentes
CN117500916A (zh) 2021-04-16 2024-02-02 博恩赛尔公司 制备、扩增和纯化中脑多巴胺能祖细胞的方法
CN113116933A (zh) * 2021-04-26 2021-07-16 河北医科大学第四医院 一种防治糖尿病足的干细胞组合物及其应用
CN114600872A (zh) * 2022-04-13 2022-06-10 西安北光医学生物技术有限公司 一种细胞、组织或器官的抗损伤保存的方法及保存系统
WO2024177862A1 (fr) * 2023-02-20 2024-08-29 Intabio, Llc Procédés d'étalonnage d'un système de spectrométrie de masse

Family Cites Families (108)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5744347A (en) 1987-01-16 1998-04-28 Ohio University Edison Biotechnology Institute Yolk sac stem cells and their uses
DE68928914T2 (de) 1988-08-04 1999-09-09 Amrad Corp. Ltd. (in vitro)-vermehrung von embryonalen stammzellen unter verwendung von leukämie-inhibitionsfaktor (lif)
US5256560A (en) 1988-10-07 1993-10-26 University Of Saskatchewan Primitive cell colony stimulating factors and lymphohematopoietic progenitor cells
US5411883A (en) 1989-12-26 1995-05-02 Somatix Therapy Corporation Proliferated neuron progenitor cell product and process
US5061620A (en) 1990-03-30 1991-10-29 Systemix, Inc. Human hematopoietic stem cell
US5622853A (en) 1990-05-01 1997-04-22 Becton Dickinson And Company T lymphocyte precursor
US5840580A (en) 1990-05-01 1998-11-24 Becton Dickinson And Company Phenotypic characterization of the hematopoietic stem cell
DE69131393T2 (de) 1990-09-10 1999-11-04 Takeda Chemical Industries, Ltd. Menschlicher Rezeptor für luteinisierendes Hormon und Choriongonadotropin
US5486359A (en) 1990-11-16 1996-01-23 Osiris Therapeutics, Inc. Human mesenchymal stem cells
US5851832A (en) 1991-07-08 1998-12-22 Neurospheres, Ltd. In vitro growth and proliferation of multipotent neural stem cells and their progeny
US6410320B1 (en) 1992-03-02 2002-06-25 The University Of Michigan Method and compositions for isolation and growth of kidney tubule stem cells, in vitro kidney tubulogenesis and ex vivo construction of renal tubules
AU658065B2 (en) 1992-03-23 1995-03-30 Nexell Therapeutics Inc. (In vitro)-derived human neutrophil precursor cells
AU4543193A (en) 1992-06-22 1994-01-24 Henry E. Young Scar inhibitory factor and use thereof
US5589376A (en) 1992-07-27 1996-12-31 California Institute Of Technology Mammalian neural crest stem cells
US5453357A (en) 1992-10-08 1995-09-26 Vanderbilt University Pluripotential embryonic stem cells and methods of making same
US5690926A (en) 1992-10-08 1997-11-25 Vanderbilt University Pluripotential embryonic cells and methods of making same
AU5603894A (en) 1992-11-16 1994-06-08 Applied Immune Sciences, Inc. Pluripotential quiescent stem cell population
DE4240635C2 (de) 1992-12-03 1997-07-10 Lothar Prof Dr Kanz Vermehrung hämatopoetischer Vorläuferzellen ex vivo sowieZusammensetzungen hämatopoetischer Wachstumsfaktoren
WO1995005843A1 (fr) 1993-08-25 1995-03-02 Systemix, Inc. Procede de production d'une population de cellules souches hematopoietiques fortement enrichie
US5453457A (en) 1993-11-12 1995-09-26 Bayer Corporation Gamma-radiation-resistant polycarbonate composition
US5972627A (en) 1994-06-15 1999-10-26 Systemix, Inc. Method of purifying a population of cells enriched for dendritic and/or lymphoid progenitors and populations of cells obtained thereby
US5650317A (en) 1994-09-16 1997-07-22 Michigan State University Human breast epithelial cell type with stem cell and luminal epithelial cell characteristics
US5677136A (en) 1994-11-14 1997-10-14 Systemix, Inc. Methods of obtaining compositions enriched for hematopoietic stem cells, compositions derived therefrom and methods of use thereof
US5874301A (en) 1994-11-21 1999-02-23 National Jewish Center For Immunology And Respiratory Medicine Embryonic cell populations and methods to isolate such populations
US5914268A (en) 1994-11-21 1999-06-22 National Jewish Center For Immunology & Respiratory Medicine Embryonic cell populations and methods to isolate such populations
US5843780A (en) 1995-01-20 1998-12-01 Wisconsin Alumni Research Foundation Primate embryonic stem cells
US5821108A (en) 1995-04-07 1998-10-13 The Board Of Trustees Of The Leland Stanford Junior University Enrichment for a thymocyte subset having progenitor cell activity using c-kit as a selection marker
US5876956A (en) 1995-05-15 1999-03-02 Johns Hopkins University School Of Medicine Methods for identification or purification of cells containing an enzymatic intracellular marker
US5908782A (en) 1995-06-05 1999-06-01 Osiris Therapeutics, Inc. Chemically defined medium for human mesenchymal stem cells
US6517872B1 (en) 1995-06-12 2003-02-11 Yeda Research And Development Co., Ltd. FGFR3 as a marker for mesenchymal skeletal progenitor cells
US5753505A (en) 1995-07-06 1998-05-19 Emory University Neuronal progenitor cells and uses thereof
GB9514816D0 (en) 1995-07-19 1995-09-20 Ucli Ltd Substances and their medical use
US5858782A (en) 1995-11-13 1999-01-12 Regents Of The University Of Michigan Functional human hematopoietic cells
US5997871A (en) 1996-06-24 1999-12-07 University Of Maryland Biotechnology Insitute Treatment and prevention of cancer by administration of derivatives of human chorionic gonadotropin
US6969608B1 (en) 1996-08-26 2005-11-29 Mcgill University Pharmaceuticals containing multipotential precursor cells from tissues containing sensory receptors
US6890724B2 (en) 1996-09-06 2005-05-10 California Institute Of Technology Methods and compositions for neural progenitor cells
US6028064A (en) 1996-09-13 2000-02-22 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of progestin products
CA2216439A1 (fr) 1996-09-25 1998-03-25 Derek Van Der Kooy Produits pharmaceutiques contenant des cellules souches retiniennes
JP2001508302A (ja) 1997-01-10 2001-06-26 ライフ テクノロジーズ，インコーポレイテッド 胚性幹細胞血清置換
US6090622A (en) 1997-03-31 2000-07-18 The Johns Hopkins School Of Medicine Human embryonic pluripotent germ cells
US6331406B1 (en) 1997-03-31 2001-12-18 The John Hopkins University School Of Medicine Human enbryonic germ cell and methods of use
US6583109B1 (en) 1997-06-24 2003-06-24 Robert C. Gallo Therapeutic polypeptides from β-hCG and derivatives
US6734015B1 (en) 1997-07-04 2004-05-11 University Of Utah Research Foundation Isolation of lineage-restricted neuronal precursors
US6908763B1 (en) 1997-08-22 2005-06-21 The Board Of Trustees Of The Leland Stanford Junior University Mammalian common lymphoid progenitor cell
US5968829A (en) 1997-09-05 1999-10-19 Cytotherapeutics, Inc. Human CNS neural stem cells
US6245757B1 (en) 1997-10-03 2001-06-12 Research Corporation Technologies, Inc. Use of progestins to treat ischemic event
JP3880795B2 (ja) 1997-10-23 2007-02-14 ジェロン・コーポレーション フィーダー細胞を含まない培養物中で、霊長類由来始原幹細胞を増殖させるための方法
AU753975B2 (en) 1997-12-04 2002-10-31 Duke University Methods of isolating and using CD7+CD34-Lin-hematopoietic cells
US6852533B1 (en) 1998-01-23 2005-02-08 Cornell Research Foundation, Inc. Purified populations of stem cells
AUPP244498A0 (en) * 1998-03-18 1998-04-09 Medvet Science Pty. Ltd. Keratinocyte stem cells
US6812027B2 (en) 1998-03-25 2004-11-02 Cornell Research Foundation, Inc. Discovery, localization, harvest, and propagation of an FGF2 and BDNF-responsive population of neural and neuronal progenitor cells in the adult human forebrain
US6835567B1 (en) 1998-04-14 2004-12-28 Signal Pharmaceuticals, Inc. PNS cell lines and methods of use therefor
ATE368731T1 (de) 1998-05-29 2007-08-15 Osiris Therapeutics Inc Menschliche cd45+ und/oder fibroblasten+ mesenchymale stammzellen
US6129911A (en) 1998-07-10 2000-10-10 Rhode Island Hospital, A Lifespan Partner Liver stem cell
US6913925B1 (en) 1998-08-12 2005-07-05 Signal Pharmaceuticals Llc Human mesencephalon cell lines and methods of use therefor
DE19837438A1 (de) 1998-08-18 2000-02-24 Biotechnolog Forschung Gmbh Rekombinante Humanzelle für Knochen- und Knorpelzellbildung
US6767737B1 (en) 1998-08-31 2004-07-27 New York University Stem cells bearing an FGF receptor on the cell surface
US6667176B1 (en) 2000-01-11 2003-12-23 Geron Corporation cDNA libraries reflecting gene expression during growth and differentiation of human pluripotent stem cells
WO2000035464A1 (fr) 1998-12-16 2000-06-22 Tsentr Embrionalnykh Tkanei 'emcell' Procede permettant de soigner des personnes a l'aide de suspensions cellulaires de tissus embryonnaires
EP1156822B1 (fr) 1999-02-24 2006-02-08 Novo Nordisk A/S Methose in vitro pour la synchronisation de la maturation des oocytes
US6777231B1 (en) 1999-03-10 2004-08-17 The Regents Of The University Of California Adipose-derived stem cells and lattices
CA2377135A1 (fr) 1999-04-23 2000-11-02 Ceptyr, Inc. Kinase phosphatase dsp-10 a double specificite activee par un mitogene
US6355648B1 (en) 1999-05-04 2002-03-12 American Home Products Corporation Thio-oxindole derivatives
US6407101B1 (en) 1999-05-04 2002-06-18 American Home Products Corporation Cyanopyrroles
US6761883B2 (en) 1999-06-29 2004-07-13 The Board Of Trustees Of The Leland Stanford Junior University Mammalian myeloid progenitor cell subsets
DE60036470T2 (de) 1999-06-29 2008-06-19 The Board Of Trustees Of The Leland Stanford Junior University, Palo Alto Untereinheiten von myeloid-progenitorzellen von säugern
US6872389B1 (en) 1999-07-08 2005-03-29 Rhode Island Hospital Liver stem cell
US6043235A (en) 1999-07-21 2000-03-28 Research Triangle Institute 11β-aryl-17, 17-spirothiolane-substituted steroids
CA2386536A1 (fr) 1999-09-14 2001-03-22 The Children's Medical Center Corporation Methodes de traitement des dystrophies musculaires
EP1212404A2 (fr) 1999-09-14 2002-06-12 Children's Medical Center Corporation Isolation de cellules souches derivees de muscle et utilisations associees
US20030082155A1 (en) 1999-12-06 2003-05-01 Habener Joel F. Stem cells of the islets of langerhans and their use in treating diabetes mellitus
US6753153B2 (en) 1999-12-13 2004-06-22 The Scripps Research Institute Markers for identification and isolation of pancreatic islet α and β progenitors
US6416999B1 (en) 2000-04-07 2002-07-09 Raven Biotechnologies, Inc. Human Müllerian duct-derived epithelial cells and methods of isolation and uses thereof
US6436704B1 (en) 2000-04-10 2002-08-20 Raven Biotechnologies, Inc. Human pancreatic epithelial progenitor cells and methods of isolation and use thereof
UA73119C2 (en) 2000-04-19 2005-06-15 American Home Products Corpoir Derivatives of cyclic thiocarbamates, pharmaceutical composition including noted derivatives of cyclic thiocarbamates and active ingredients of medicines as modulators of progesterone receptors
EP1276486B2 (fr) 2000-04-25 2014-03-05 Osiris Therapeutics, Inc. Reparation des articulations utilisant des cellules souches mesenchymateuses
NL1017973C2 (nl) 2000-05-10 2002-11-08 Tristem Trading Cyprus Ltd Inrichting.
US6936281B2 (en) 2001-03-21 2005-08-30 University Of South Florida Human mesenchymal progenitor cell
US6921632B2 (en) 2000-08-30 2005-07-26 Maria Biotech Co., Ltd. Human embryonic stem cells derived from frozen-thawed embryo
US20040071665A1 (en) 2000-09-05 2004-04-15 Yong-Fu Xiao Method for therapeutically treating a clinically recognized form of cardiopathology in a living mammal
US6458588B1 (en) 2001-01-31 2002-10-01 The General Hospital Corporation Renal stem cells and uses thereof
EP1367899A4 (fr) 2001-02-14 2004-07-28 Leo T Furcht Cellules souches adultes totipotentes, sources de ces cellules, procedes d'obtention et de maintien de ces dernieres, procedes de differentiation de ces cellules, procedes d'utilisation correspondants et cellules derivees des cellules susmentionnees
US6852532B2 (en) 2001-03-21 2005-02-08 University Of Utah Research Foundation Method of isolating human neuroepithelial precursor cells from human fetal tissue
CA2442177A1 (fr) 2001-03-29 2002-10-10 Ixion Biotechnology, Inc. Procede de transdifferentiation de cellules souches non pancreatiques dans la voie de differentiation du pancreas
US20030017587A1 (en) 2001-07-18 2003-01-23 Rader William C. Embryonic stem cells, clinical applications and methods for expanding in vitro
DE10139783C1 (de) 2001-08-14 2003-04-17 Transtissue Technologies Gmbh Zellzusammensetzungen zur Behandlung von Osteoarthrose, sowie Verfahren zu deren Herstellung
JP2005523685A (ja) * 2001-11-06 2005-08-11 上海第二医科大学 体細胞由来胚幹細胞及びそれらの分化子孫
JP4330995B2 (ja) 2001-11-15 2009-09-16 チルドレンズ メディカル センター コーポレーション 絨毛膜絨毛、羊水、および胎盤からの胎児性幹細胞を単離、増殖、および分化させる方法、ならびにその治療的使用方法
WO2003046141A2 (fr) * 2001-11-26 2003-06-05 Advanced Cell Technology, Inc. Procedes de production et d'utilisation de noyaux de cellules somatiques humaines reprogrammees et de cellules souches humaines autologues et isogeniques
CN100579577C (zh) * 2002-03-15 2010-01-13 退伍军人事务研发服务部 使用细胞脱唾液酸决定簇和糖缀合物将细胞靶向组织和器官的方法和组合物
US20040009589A1 (en) * 2002-03-26 2004-01-15 Shulamit Levenberg Endothelial cells derived from human embryonic stem cells
US7285415B2 (en) * 2002-07-11 2007-10-23 The Regents Of The University Of California Oligodendrocytes derived from human embryonic stem cells for remyelination and treatment of spinal cord injury
KR20110102961A (ko) 2002-07-25 2011-09-19 더 스크립스 리서치 인스티튜트 조혈 줄기세포 및 이를 사용한 신생혈관 안구 질환의 치료방법
EP1558618A1 (fr) 2002-10-11 2005-08-03 Ligand Pharmaceuticals, Inc. 5-(1',1'-cycloalkyl/alcenyl)methylidene 1,2-dihydro- i 5h /i -chromeno 3,4- i f /i ]quinolines utilisees comme composes modulateurs du recepteur de la progesterone selectifs
TW200410968A (en) 2002-10-11 2004-07-01 Ligand Pharm Inc 5-cycloalkenyl 5H-chromeno[3,4-f]quinoline derivatives as selective progesterone receptor modulator compounds
NZ539713A (en) * 2002-10-11 2008-07-31 Novocell Inc Implantation of encapsulated biological materials for treating diseases
AU2003285172A1 (en) * 2002-11-08 2004-06-03 The Johns Hopkins University Human embryonic stem cell cultures, and compositions and methods for growing same
UA59678A (uk) 2002-11-15 2003-09-15 Національний Медичний Університет Ім. О.О. Богомольця Спосіб лікування ревматоїдного артриту
RU2345133C2 (ru) * 2003-03-12 2009-01-27 Релайанс Лайф Сайенсиз Пвт. Лтд. Получение терминально дифференцированных дофаминергических нейронов из эмбриональных стволовых клеток человека
AU2004269361B2 (en) 2003-08-29 2010-05-20 Wisconsin Alumni Research Foundation Method of in vitro differentiation of neural stem cells, motor neurons and dopamine neurons from primate embryonic stem cells
WO2005047524A2 (fr) 2003-11-10 2005-05-26 The Scripps Research Institute Compositions et procedes pour induire la differenciation cellulaire
US20050106554A1 (en) 2003-11-19 2005-05-19 Palecek Sean P. Cryopreservation of pluripotent stem cells
UA71388A (uk) 2003-12-26 2004-11-15 Інститут Нейрохірургії Імені Академіка А. П. Ромоданова Академії Медичних Наук України Спосіб отримання збагаченої суспензії стовбурових нейральних клітин
WO2005065354A2 (fr) * 2003-12-31 2005-07-21 The Burnham Institute Milieu défini pour culture de cellules souches pluripotentes
US20070298453A1 (en) 2004-02-12 2007-12-27 University Of Newcastle Upon Tyne Stem Cells
WO2005099758A2 (fr) * 2004-04-17 2005-10-27 The Board Of Trustees The Leland Standford Junior University Matrice de tissu bioartificielle injectable
CA2583473A1 (fr) 2004-10-05 2007-04-04 University Of Georgia Research Foundation, Inc. Progeniteurs neuronaux obtenus par culture de cellules souches embryonnaires humaines sans cellules nourricieres
AP2949A (en) 2006-03-07 2014-07-31 Shroff Geeta Compositions comprising human embryonic stem cellsand their derivatives, methods of use, and method s of preparation

Also Published As

Publication number Publication date
IL193702A (en) 2015-02-26
US20090123433A1 (en) 2009-05-14
EP2422803A3 (fr) 2013-03-13
US20140057250A1 (en) 2014-02-27
US20140051110A1 (en) 2014-02-20
AU2007257594B2 (en) 2012-11-01
US20140050706A1 (en) 2014-02-20
EP2422796A2 (fr) 2012-02-29
EP2422798A2 (fr) 2012-02-29
EA200801943A1 (ru) 2009-04-28
EP2422801A2 (fr) 2012-02-29
EP2422795A3 (fr) 2013-03-13
NZ594639A (en) 2013-04-26
US9488643B2 (en) 2016-11-08
US20140057350A1 (en) 2014-02-27
EP2422802A2 (fr) 2012-02-29
US9134299B2 (en) 2015-09-15
MX347303B (es) 2017-04-21
EA027648B9 (ru) 2018-01-31
AP2008004623A0 (en) 2008-10-31
CN101420964A (zh) 2009-04-29
JP2014159455A (ja) 2014-09-04
US20190369088A1 (en) 2019-12-05
EP2422794A2 (fr) 2012-02-29
PH12014501028A1 (en) 2016-02-22
EP2422797A3 (fr) 2013-03-20
JP2009528834A (ja) 2009-08-13
CN103893211A (zh) 2014-07-02
EP1993575B1 (fr) 2019-07-03
EP2422799A2 (fr) 2012-02-29
CU20080161A7 (es) 2012-11-15
IL193702A0 (en) 2011-08-01
EP2422797A2 (fr) 2012-02-29
AU2007257594A1 (en) 2007-12-13
EP2422795A2 (fr) 2012-02-29
KR20080106332A (ko) 2008-12-04
CR10345A (es) 2009-03-30
WO2007141657B1 (fr) 2008-07-31
EP2422800A3 (fr) 2013-03-06
EP2422801A3 (fr) 2013-03-06
EA027648B1 (ru) 2017-08-31
EP2422794A3 (fr) 2013-03-13
EP2422802A3 (fr) 2013-03-06
US20140051164A1 (en) 2014-02-20
US20130122588A1 (en) 2013-05-16
DK1993575T3 (da) 2019-10-14
EP2422803A2 (fr) 2012-02-29
GEP20135796B (en) 2013-04-10
US8592208B2 (en) 2013-11-26
EP2422799A3 (fr) 2013-03-06
US9482660B2 (en) 2016-11-01
KR101505382B1 (ko) 2015-03-23
WO2007141657A2 (fr) 2007-12-13
US10545135B2 (en) 2020-01-28
AP2949A (en) 2014-07-31
US20130122486A1 (en) 2013-05-16
JP5649786B2 (ja) 2015-01-07
BRPI0708576A2 (pt) 2011-05-31
EP1993575A2 (fr) 2008-11-26
CA2644922C (fr) 2019-07-23
MX2008011279A (es) 2008-11-25
MY154677A (en) 2015-07-15
US8900861B2 (en) 2014-12-02
KR20140135263A (ko) 2014-11-25
US9804151B2 (en) 2017-10-31
EP2422800A2 (fr) 2012-02-29
CA2644922A1 (fr) 2007-12-13
ECSP088799A (es) 2008-12-30
NO20084181L (no) 2008-11-26
EP2422796A3 (fr) 2013-03-13
EP2422798A3 (fr) 2013-03-06
WO2007141657A3 (fr) 2008-04-24
NZ571127A (en) 2012-01-12
KR101505202B1 (ko) 2015-03-27
US9383349B2 (en) 2016-07-05

Similar Documents

Publication Publication Date Title
MA30323B1 (fr) Compositions comprenant des cellules souches embryonnaires humaines et leurs derives, procedes d'utilisation et procedes de preparation
Duarte et al. Effect of a novel type of propolis and its chemical fractions on glucosyltransferases and on growth and adherence of mutans streptococci
Barger et al. S100 beta stimulates calcium fluxes in glial and neuronal cells.
Jabłońska-Trypuć et al. Traumatic acid reduces oxidative stress and enhances collagen biosynthesis in cultured human skin fibroblasts
DK2828409T3 (en) Method for Single Nucleotide Detection
ES2503340T3 (es) Composiciones a base de Arthrospira y usos de los mismos
US20060084135A1 (en) Compositions for manipulating the lifespan and stress response of cells and organisms
KR20140014318A (ko) 세포 보존용 수용액
Zhang et al. Inhibition of aldehyde dehydrogenase 2 activity enhances antimycin-induced rat cardiomyocytes apoptosis through activation of MAPK signaling pathway
JP5951491B2 (ja) トリプトリドの製造方法
Zhang et al. Effect of pentoxifylline in reducing oxidative stress-induced embryotoxicity
ES2554502T3 (es) Método para prolongar el período de movilidad estacional de los peces
Hegazi In vitro studies on Delonix elata L., an endangered medicinal plant
DiSorbo et al. In vivo and in vitro inhibition of B16 melanoma growth by vitamin B6
CN115297928A (zh) 受精卵的碎片化抑制剂
JP4912720B2 (ja) 茸由来破骨細胞形成阻害剤
EP3223840A1 (fr) Extraits titrés de cynara scolymus et leurs utilisations
Useh et al. The inhibition of Clostridium chauvoei (jakari strain) neuraminidase activity by methanolic extracts of the stem barks of Tamarindus indicus and Combretum fragrans
FR3061208B1 (fr) Adjuvants pour milieux de culture cellulaire, notamment pour fecondation in vitro, ou pour la culture de follicules, cellules germinales males ou embryons
Kišidayová et al. Regeneration of cryoresistance of in vitro rumen ciliate cultures
Kurniawan et al. Intermolecular [4+ 2]-cycloaddition reaction to biotransform morachalcone A into kuwanon J, catalyzed by Diels-Alderase from a root culture of Morus alba var. shalun (M. shalun).
KR20120082226A (ko) Ｇｐｒ92를 저해하는 화합물을 포함하는 항 신경성 통증 또는 항 혈전 약학조성물
KR890003081B1 (ko) 세포배양에 사용하기 위한 첨가물, 무혈청 배양용 배지 및 그것들을 사용하는 세포배양법
TWI419973B (zh) 提高超氧歧化酶活性之方法
RU2681116C2 (ru) Питательная среда плотная для хранения микроба чумы